1. Home
  2. VCEL vs NVAX Comparison

VCEL vs NVAX Comparison

Compare VCEL & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vericel Corporation

VCEL

Vericel Corporation

HOLD

Current Price

$46.23

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.88

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VCEL
NVAX
Founded
1989
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
VCEL
NVAX
Price
$46.23
$8.88
Analyst Decision
Strong Buy
Hold
Analyst Count
5
9
Target Price
$57.75
$11.33
AVG Volume (30 Days)
598.5K
4.4M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
60.00
309.76
EPS
N/A
N/A
Revenue
$276,259,000.00
$1,123,479,000.00
Revenue This Year
$19.40
N/A
Revenue Next Year
$18.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.45
64.69
52 Week Low
$28.95
$6.20
52 Week High
$43.57
$11.85

Technical Indicators

Market Signals
Indicator
VCEL
NVAX
Relative Strength Index (RSI) 81.81 46.20
Support Level $32.47 $8.89
Resistance Level N/A $9.02
Average True Range (ATR) 1.61 0.60
MACD 0.70 -0.08
Stochastic Oscillator 96.76 36.52

Price Performance

Historical Comparison
VCEL
NVAX

About VCEL Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: